재생 의료용 콜라겐 및 젤라틴은 2024년 시장 규모는 9억 5,428만 달러로 평가되었으며, 2024년부터 2031년까지의 연평균 성장률(CAGR)은 7.6%로 성장하여 2031년에는 16억 2,613만 달러에 이를 것으로 예상됩니다. 콜라겐은 피부, 관절, 뼈와 같은 결합 조직에 존재하는 신체에서 가장 흔한 단백질로, 구조와 안정성을 제공합니다. 젤라틴은 콜라겐이 부분적으로 가수분해되어 삼중나선 구조가 변성된 것입니다. 콜라겐과 젤라틴은 생체 적합성, 세포 인식 부위, 조정 가능한 생분해성으로 재생 의료에 사용되어 조직 공학, 세포 치료, 약제 투여 강화에 있어서 획기적인 진보를 가능하게 하고 있습니다.
또한, 콜라겐 스캐폴드는 세포의 발달과 침착을 촉진하는데 도움이 되며, 젤라틴의 독특한 특성은 그것을 변경하여 생물학적 및 기능적 특성을 개선할 수 있게 하여 조직 재생을 지원하는 새로운 바이오 재료의 길을 열어줍니다.
만성 질환 및 부상의 유병률 증가 :
조직의 복구 및 재생을 필요로 하는 만성 질환 및 부상의 유병률 증가는 재생 의료용 콜라겐 및 젤라틴 시장의 주요 촉진요인입니다. 세계보건기구(WHO)에 따르면, 전 세계 사망자의 71%가 만성 질환으로 인해 발생하며 이는 연간 4,100만 명을 차지하고 있습니다. 미국 질병 예방관리센터(CDC)에 따르면 미국 성인의 약 4명 중 1명(26%)이 어떠한 장애를 앓고 있으며, 그 대부분이 콜라겐과 젤라틴을 이용한 재생 의료 치료의 혜택을 받을 수 있습니다.
고령화 인구 증가:
세계 고령화는 재생 의료용 콜라겐 및 젤라틴 솔루션에 대한 수요를 증가시키고 있습니다. 세계 인구 전망에 따르면, 2050년까지 전 세계 인구의 16%가 65세 이상일 것으로 예상됩니다. 인구동태의 변화는 미국에서만 추정 3,250만 명이 앓고 있는 변형성 관절증과 같은 노화와 관련된 질병의 유병률을 밀어 올리고 있습니다. 이러한 노화와 관련된 문제에 대처할 수 있는 가능성이 시장 확대의 원동력이 되고 있습니다.
조직 공학 및 재생 의학 연구의 발전 :
조직 공학과 재생 의학에서 지속적인 연구 및 개발이 재생 의료용 콜라겐 및 젤라틴 시장을 발전시키고 있습니다. ARM(Alliance for Regenerative Medicine)의 보고에 따르면 2020년 말까지 세계 1,220건의 재생 의료와 첨단 치료 임상시험이 실시되었으며, 그 중 많은 부분이 콜라겐과 젤라틴을 이용한 기술을 포함한다고 밝혔습니다.
주요 과제
대체 생체 재료의 가용성 :
키토산, 알긴산, 히알루론산과 같은 대체 생체 재료의 출현은 콜라겐 및 젤라틴 제품의 성장에 제약이 따릅니다. 헬스케어 산업에서 이러한 대체재의 채택이 증가함에 따라 콜라겐 젤라틴 기반 제품의 성장 가능성이 제한되고 시장 역학에 심각한 영향을 미칩니다.
제조 단위 별 편차 및 품질 관리 문제 :
콜라겐과 젤라틴 제품은 각 제조단위의 일관성을 보장하는 것이 어려우며 품질 관리 문제를 일으키고 있습니다. 또한 정제 및 품질 관리가 어려우므로 연구자와 임상의가 재생 의료에서 이러한 제품의 광범위한 사용이 제한됩니다.
주요 동향 :
식물 유래의 지속 가능한 원료에 대한 수요 증가 :
콜라겐 및 젤라틴은 주로 동물에서 유래되기 때문에 윤리적 및 환경적 우려로 인해 소비자는 식물 유래의 지속 가능한 콜라겐과 젤라틴 공급 원료를 점점 선호하고 있습니다. 이에 따라 해조류 및 쌀 단백질과 같은 식물 기반 대체 품목이 만들어지고 있습니다. 기업은 재생 의료 용도에서 식물 유래의 대체물에 대한 수요 증가에 대응하기 위해 보다 효율적이고 환경 친화적인 생산 공정를 개발하는 연구에 투자하고 있습니다.
고급 상처 관리 및 조직 공학에서 활용 증가 :
콜라겐과 젤라틴은 높은 생체적합성, 생분해성 및 세포의 발달과 조직 재생을 촉진하는 능력에 의해 고급 상처 치료 및 조직 공학에 점점 더 많이 사용되고 있습니다. 기업들은 상처 치유, 뼈 재생 및 장기 대체를 위한 혁신적인 콜라겐 및 젤라틴 기반 솔루션을 개발하기 위해 연구개발에 투자하고 있습니다. 만성 상처, 당뇨병 및 암의 유병률 증가가 이러한 고급 재생 의료 솔루션 수요를 촉진하고 있습니다.
Collagen and Gelatin Market for Regenerative Medicine Market size was valued at USD 954.28 Million in 2024 and is projected to reach USD 1626.13 Million by 2031, growing at a CAGR of 7.6% from 2024 to 2031. Collagen is the body's most prevalent protein, found in connective tissues such as skin, joints, and bones, where it provides structure and stability. Gelatin is a deteriorated form of collagen that results from partial hydrolysis, which denatures the triple helical structure. Collagen and gelatin are employed in regenerative medicine due to their biocompatibility, cell recognition sites, and tunable biodegradability, which enable breakthroughs in tissue engineering, cellular treatment, and enhanced drug administration.
Furthermore, collagen scaffolds promote cell development and deposition, but gelatin's unique features allow it to be changed to improve its biological and functional qualities, opening up new avenues for biomaterials that can support tissue regeneration.
The key market dynamics that are shaping the collagen and gelatin market for regenerative medicine market include:
Increasing Prevalence of Chronic Diseases and Injuries:
The increasing prevalence of chronic diseases and injuries necessitating tissue repair and regeneration is a major driver of the collagen and gelatin market for regenerative medicine. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, or 41 million people per year. According to the Centers for Disease Control and Prevention (CDC), approximately one in every four adults (26%) in the United States suffers from some form of impairment, many of which could benefit from regenerative medicine treatments utilizing collagen and gelatin.
Growing Aging Population:
The worldwide aging population is boosting demand for regenerative medicine solutions based on collagen and gelatin. According to the United Nations World Population Prospects 2019 report, by 2050, one in every six individuals will be beyond the age of 65 (16%), up from one in every eleven (9%). This demographic change is driving up the prevalence of age-related illnesses like osteoarthritis, which affects an estimated 32.5 million individuals in the United States alone, according to the CDC. The potential for collagen and gelatin-based medicines to address these age-related problems is driving market expansion.
Advancements in Tissue Engineering and Regenerative Medicine Research:
Continuous research and development in tissue engineering and regenerative medicine are driving the collagen and gelatin market forward. The National Institutes of Health (NIH) reports that it invested around USD 2.5 Billion in regenerative medicine research in fiscal year 2020. Also, the Alliance for Regenerative Medicine reports that 1,220 clinical trials in regenerative medicine and advanced therapies will be underway worldwide by the end of 2020, with many of them involving collagen and gelatin-based techniques.
Key Challenges:
Availability of Alternative Biomaterials:
The emergence of replacement biomaterials such as chitosan, alginate, and hyaluronic acid presents a substantial challenge to the collagen and gelatin market. These alternatives offer equivalent or superior healing and regeneration qualities, prompting a shift in choice among manufacturers and healthcare professionals. As these replacements acquire popularity, they limit the growth potential of collagen and gelatin-based products in regenerative applications, severely affecting market dynamics.
Batch Variability and Quality Control Issues:
Collagen and gelatin products have batch-to-batch variability, raising issues about uniformity and quality. This unpredictability complicates the manufacturing process and reduces the dependability of these biomaterials in therapeutic settings. Furthermore, difficulties with purification and quality control prevent researchers and clinicians from completely adopting these products, restricting their widespread use in regenerative medicine.
Key Trends:
Growing Demand for Plant-Based and Sustainable Sources:
Consumers are increasingly preferring plant-based and sustainable sources of collagen and gelatin, driven by ethical and environmental concerns. This has resulted in the creation of novel alternatives derived from seaweed, rice protein, and pea protein. Companies are investing in research to develop more efficient and environmentally friendly production processes to address the growing demand for plant-based alternatives in regenerative medical applications.
Increasing Use in Advanced Wound Care and Tissue Engineering:
Collagen and gelatin are increasingly being used in advanced wound care and tissue engineering due to their high biocompatibility, biodegradability, and ability to encourage cell development and tissue regeneration. Companies are investing in R&D to develop innovative collagen and gelatin-based solutions for wound healing, bone regeneration, and organ replacement. The increasing prevalence of chronic wounds, diabetes, and cancer is fueling the demand for these advanced regenerative medicine solutions.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the collagen and gelatin market for regenerative medicine market:
North America:
According to Verified Market Research, North America is estimated to dominate the collagen and gelatin market for regenerative medicine market over the forecast period. North America, particularly the United States, has a high prevalence of chronic diseases and injuries that could benefit from regenerative medicine treatments based on collagen and gelatin. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. According to the CDC, approximately 54.4 million US individuals (or around 23%) have doctor-diagnosed arthritis, a condition for which collagen-based medicines show promise. The region's high disease load increases the demand for innovative regenerative medicine treatments.
Furthermore, North America is at the forefront of regenerative medicine research and development, which is driving the collagen and gelatin market. The California Institute for Regenerative Medicine (CIRM), the United States' largest state-funded stem cell agency, has committed more than USD 3 Billion in regenerative medicine research since its creation. In addition, the National Institutes of Health (NIH) reported funding for regenerative medicine research of around USD 2.5 Billion in fiscal year 2020. This large investment supports regional innovation and market growth.
Asia Pacific:
The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia Pacific region's aging population is rapidly growing, resulting in increased demand for regenerative medicine solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In East and North-East Asia, the population aged 65 and up is expected to grow from 260 million in 2020 to 573 million by 2050. This demographic shift increases the demand for collagen and gelatin-based regenerative medicines to address age-related health concerns.
Furthermore, the Asia Pacific region is experiencing an increase in chronic diseases, resulting in a significant market for regenerative medicine. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for 71% of all deaths worldwide, with a disproportionate impact on low- and middle-income nations, the majority of which are in Asia. According to the International Diabetes Federation (IDF), the number of adults with diabetes in Southeast Asia is anticipated to grow from 88 million in 2019 to 153 million by 2045. This increased illness load is encouraging the use of advanced regeneration treatments such as collagen and gelatin.
Europe:
Europe region is estimated to exhibit substantial growth within the market during the forecast period. Europe has one of the world's oldest populations, which fuels demand for regenerative medicine treatments. According to Eurostat, the proportion of adults 65 and older in the EU-27 is expected to rise from 20.3% in 2019 to 29.4% by 2050. This demographic transition coincides with an increase in age-related ailments. For example, the European League Against Rheumatism (EULAR) estimates that over 120 million people in the EU suffer from rheumatic and musculoskeletal illnesses (RMDs), many of which could benefit from collagen and gelatin-based regenerative therapies. The aging population and accompanying health challenges are driving the regenerative medicine market in Europe.
Furthermore, Europe is witnessing an increasing burden of chronic diseases, providing a sizable market for regenerative medicine treatments. Chronic diseases, according to the World Health Organization (WHO), account for 86% of fatalities and 77% of disease burden in Europe. The European Heart Network states that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. Many of these chronic illnesses benefit from collagen and gelatin-based regenerative therapies, resulting in market expansion.
The Global Collagen and Gelatin Market for Regenerative Medicine Market is segmented based on Source, Application, and Geography.
Based on Source, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Bovine, Porcine, Marine, and Others. The bovine segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the extensive use of bovine-derived collagen and gelatin, which are highly biocompatible and biodegradable. Because of the huge scale of cow ranching, bovine supplies are frequently less expensive, making them a preferred alternative for a variety of regenerative medicine applications such as wound care and orthopedic operations, resulting in market leadership.
Based on Application, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Wound Care, Orthopedic, Cardiovascular, and Others. The orthopedic segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the increasing use of collagen and gelatin-based biomaterials in orthopedic procedures such as joint replacements and bone restoration. The rising prevalence of orthopedic disorders, combined with advances in surgical procedures and product improvements, has greatly increased demand for these materials, making orthopedics the market's largest application segment.
Based on Geography, the Collagen and Gelatin market for regenerative medicine market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to dominate the market during the forecasted period due to the high prevalence of chronic diseases, a well-developed healthcare infrastructure, and the existence of major market participants. The region's excellent research capabilities and major investments in regenerative medicine strengthen its position. Furthermore, the growing use of collagen-based products in a variety of medical applications, such as wound care and orthopedic procedures, helps North America maintain its market leadership.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.